Lindsay Dahora

Lindsay Dahora

Auto-generated profile, based on publicly available information

Lindsay Dahora

Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
CJCelina Jin
Celina Jin
JHJennifer Hill
Jennifer Hill
BGBronwyn M. Gunn
Bronwyn M. Gunn
WYWen-Han Yu
Wen-Han Yu
LDLindsay C. Dahora
Lindsay C. Dahora
APAndrew J. Pollard
Andrew J. Pollard
Typhoid Vi vaccines have been shown to be efficacious in children living in endemic regions; however, a widely accepted correlate of protection remains to be established. We applied a systems serology approach to identify Vi-specific serological correlates of protection using samples obtained from participants enrolled in an experimental controlled human infection study. Participants were vaccinated with Vi-tetanus toxoid conjugate (Vi-TT) or unconjugated Vi-polysaccharide (Vi-PS) vaccines and were subsequently challenged with Salmonella Typhi bacteria. Multivariate analyses identified distinct protective signatures for Vi-TT and Vi-PS vaccines in addition to shared features that predicted protection across both groups. Vi IgA quantity and avidity correlated with protection from S. Typhi infection, whereas higher fold increases in Vi IgG responses were associated with reduced disease severity. Targeted antibody-mediated functional responses, particularly neutrophil phagocytosis, were also identified as important components of the protective signature. These humoral markers could be used to evaluate and develop efficacious Vi-conjugate vaccines and assist with accelerating vaccine availability to typhoid-endemic regions.

25 December 2024 in The Lancet Microbe
Verified
Journal Article
Open access
LHLindsay Dahora Hein
Lindsay Dahora Hein
ICIzabella N Castillo
Izabella N Castillo
FMFreddy A Medina
Freddy A Medina
FVFrances Vila
Frances Vila
BSBruno Segovia-Chumbez
Bruno Segovia-Chumbez
PLPremkumar Lakshmanane
Premkumar Lakshmanane
Serology for dengue viruses (DENV) and Zika virus (ZIKV) has been hindered by antibody cross-reactivity, which limits the utility of these tests for surveillance and assessment of sero-status. Our aim was to develop a multiplexed IgG-based assay with increased accuracy to assess the history of previous DENV and ZIKV infections. We developed and assessed the analytical performance of a sample-sparing, multiplexed, microsphere-based serological assay using domain III of the envelope protein (EDIII) of DENV serotypes 1-4 and ZIKV, the most variable region between each virus. We used a reference panel of well-characterised serum samples from US-based travellers or residents of southeast Asia, central America, or Puerto Rico, who were naive or immune to either or both DENV and ZIKV, to develop an algorithm for detecting previous exposure to DENV and ZIKV and identify optimal positivity cutoffs to maximise assay performance. To independently confirm the performance of the assay and algorithm, we used a second test set of previously collected samples from healthy children (aged 9-16 years) living in Puerto Rico, whose DENV and ZIKV serostatus had been defined using the gold-standard virus neutralisation assay. We evaluated the performance of the multiplex assay compared with the gold-standard assay by estimating sensitivity and specificity for identification of past exposure to ZIKV and DENV. The multiplexed EDIII assay showed reproducible results over different days and a linearity range from μg to pg levels for various EDIII antigens. Using a reference panel of serum samples from individuals who were DENV naive (n=136), DENV immune (n=38), ZIKV naive (n=67), and ZIKV immune (n=28), we optimised the assay and developed a testing algorithm that was 94·9% (95% CI 83·1-99·1) sensitive and 97·1% (92·7-98·9) specific for identifying previous exposure to DENV, and 100% (95% CI 88·0-100) sensitive and 97·0% (89·8-99·5) specific for identifying previous exposure to ZIKV. In an analysis with an independent test set of 389 samples, the assay and algorithm had 94·2% (89·9-97·1) sensitivity and 92·9% (87·3-96·5) specificity for DENV, and 94·1% (88·7-97·4) sensitivity and 95·0% (90·0-98·0) specificity for ZIKV. The multiplexed EDIII serology assay can accurately identify the history of previous infection with either DENV or ZIKV. This high-throughput and sample-sparing assay is a promising new tool for supporting flavivirus surveillance, epidemiological and clinical studies, and serological testing for dengue vaccine eligibility. Further studies are needed to reduce the cost of the assay, eliminate high background in some samples, and to assess performance in DENV-endemic and ZIKV-endemic countries. US National Institutes of Health.

1 January 2021 in Patterns
Verified
Journal Article
Open access
ATAdriana Tomic
Adriana Tomic
ITIvan Tomic
Ivan Tomic
LWLevi Waldron
Levi Waldron
LGLudwig Geistlinger
Ludwig Geistlinger
MKMax Kuhn
Max Kuhn
MDMark M Davis
Mark M Davis
Data analysis and knowledge discovery has become more and more important in biology and medicine with the increasing complexity of biological datasets, but the necessarily sophisticated programming skills and in-depth understanding of algorithms needed pose barriers to most biologists and clinicians to perform such research. We have developed a modular open-source software, SIMON, to facilitate the application of 180+ state-of-the-art machine-learning algorithms to high-dimensional biomedical data. With an easy-to-use graphical user interface, standardized pipelines, and automated approach for machine learning and other statistical analysis methods, SIMON helps to identify optimal algorithms and provides a resource that empowers non-technical and technical researchers to identify crucial patterns in biomedical data.

19 February 2020 in Gates Open Research
Verified
Journal Article
Open access
PDF file
RYRuth Young
Ruth Young
TBTewodros Bekele
Tewodros Bekele
AGAlexander Gunn
Alexander Gunn
NCNick Chapman
Nick Chapman
VCVipul Chowdhary
Vipul Chowdhary
GYGavin Yamey
Gavin Yamey
Background: Funding for neglected disease product development fell from 2009-2015, other than a brief injection of Ebola funding. One impediment to mobilizing resources is a lack of information on product candidates, the estimated costs to move them through the pipeline, and the likelihood of specific launches. This study aimed to help fill these information gaps. Methods: We conducted a pipeline portfolio review to identify current candidates for 35 neglected diseases. Using an adapted version of the Portfolio to Impact financial modelling tool, we estimated the costs to move these candidates through the pipeline over the next decade and the likely launches. Since the current pipeline is unlikely to yield several critical products, we estimated the costs to develop a set of priority “missing” products. Results: We found 685 neglected disease product candidates as of August 31, 2017; 538 candidates met inclusion criteria for input into the model. It would cost about $16.3 billion (range $13.4-19.8B) to move these candidates through the pipeline, with three-quarters of the costs incurred in the first 5 years, resulting in about 128 (89-160) expected product launches. Based on the current pipeline, there would be few launches of complex new chemical entities; launches of highly efficacious HIV, tuberculosis, or malaria vaccines would be unlikely. Estimated additional costs to launch one of each of 18 key missing products are $13.6B assuming lowest product complexity or $21.8B assuming highest complexity ($8.1B-36.6B). Over the next 5 years, total estimated costs to move current candidates through the pipeline and develop these 18 missing products would be around $4.5B (low complexity missing products) or $5.8B/year (high complexity missing products). Conclusions: Since current annual global spending on product development is about $3B, this study suggests the annual funding gap over the next 5 years is at least $1.5-2.8B.

29 October 2021 in Science Immunology
Verified
Journal Article
Closed access
LDLindsay C. Dahora
Lindsay C. Dahora
MVMarije K. Verheul
Marije K. Verheul
KWKatherine L. Williams
Katherine L. Williams
CJCelina Jin
Celina Jin
LSLisa Stockdale
Lisa Stockdale
GTGeorgia Tomaras
Georgia Tomaras
Prime-boost vaccination with S. Typhi Vi capsule induces convergent antibodies whose function depends on specificity and avidity.

15 May 2017 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
AAAllison G. Aioub
Allison G. Aioub
LDLindsay Dahora
Lindsay Dahora
KGKelly Gamble
Kelly Gamble
MFM. G. Finn
M. G. Finn